Dwight Morrow Email & Phone Number

United States

Cambridge, Massachusetts, US

• As head of Biological Sciences (BSci), I lead a diverse team of passionate scientists with broad scientific expertise. We work with business partners across Moderna from early exploratory research to later stage.
• Translational biology is responsible for the development of in vitro & ex vivo models, in vivo biodistribution studies (mRNA and protein), non-clinical PK/PD relationships, tolerability, innate immunogenicity &.
• Cell biology responsible for the study of LNP uptake, trafficking & endosomal escape of nucleic acids from LNPs including mRNA and DNA cargos.
• Analytical biology with expertise in SEC, HPLC and Mass Spec with a focus on the LNP corona (protein & lipid) and the biological role the corona plays in biodistribution, LNP stability, & reactogenicity.
• Protein science responsible for design, expression and purification of critical proteins as well as monoclonal and polyclonal production.

Cambridge, Massachusetts, US

I joined Parallel Bio as VP, Head of Platform. Parallel Bio grows best-in-class human immune organoids at scale. Immune organoids, coupled with computational and artificial intelligence enable an entirely new approach to develop safe and effective small molecule and biological drugs while gaining unprecedented insight into human immune system function not.

Cambridge, Massachusetts, US

Rubius Therapeutics focus was to transform red blood cells into potent cellular therapies for patients with rare enzyme deficiencies, cancer, and autoimmune disease. At Rubius, I led the P3 organization (Platform Innovation, Protein Sciences and Prime,) a fantastic team of highly skilled and dedicated scientists. Our job was to develop novel strategies to.

Cambridge, Massachusetts, US

Magenta Therapeutics was harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. I left GSK to join Magenta, coming in as employee #3 to help build the company and its culture. I am an inventor on Magenta’s first patents and led Magenta’s first program to IND and successful P1.

Brentford, Middlesex, GB

As a member of the department of Target Sciences, my job was to help define and implement the strategy to identify and validate new drug targets for Metabolic Pathways and Cardiovascular therapy area working very closely with highly talented geneticists, bioinformaticians, statisticians and experimental disease modeling experts. Critically important was.

Brentford, Middlesex, GB

As a member of the Regenerative Medicine and Stem Cell groups in GSK, I worked on innovative and transformative medicines and platforms in the area of regenerative medicine, stem cells, induced pluripotent stem cells and progenitor cells. Areas included hematology, hematopoietic stem cells, stem cell treatments for ophthalmology, neuroregeneration and.

Brentford, Middlesex, GB

As a member of the Stem Cell group in GSK I had primary responsibility for developing our stem cell strategy in a number of key therapeutic areas. I lead a stem cell strategy group accountable for global stem cell and induced pluripotent stem cell strategy for both safety assessment (cardiomyocytes and hepatocytes) and efficacy screening. The primary.

Brentford, Middlesex, GB

My primary responsibilities involved developing and screening cell-based assays for drug discovery. This included membrane and whole cell assays such as calcium, GTPgS, binding assay, fluorescence assays (FP, FRET, LANCE, FLINT), luciferase assays, to name a few. My group did both compound profiling and high throughput screening. Previously the group did.

Brentford, Middlesex, GB

My first position was at SB before SB became GSK. I was hired as a scientist to do cell-based technology development. Shortly after joining I was also asked to lead the cell-based high throughput screening group.

I joined Cadus to do yeast screening work using several novel technologies. Unfortunately, Cadus went out of business, remaining folks began working for OSI Inc, another biotechnology/pharmaceutical company. I worked for OSI for about four months before leaving for SmithKline Beecham.

During my post-doc I worked on double-strand break repair in yeast; TEL1, a homolog of the gene ATM mutant in Ataxia Telangiectasia; and developed novel methods for manipulating large DNA and chromosome fragments.

Phd, Molecular Immunology

Ba, Biology

Post-Doctoral Fellow, Molecular Genetics